J.L. Lee

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Toni K. Choueiri, Robert J. Motzer, Brian I. Rini et al. · Annals of Oncology · 2020 · 461 citations · Full text

Medicine, Oncology, Pharmacology +15

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

W.J. Lee, J.L. Lee, S.E. Chang et al. · British Journal of Dermatology · 2009 · 236 citations

Medicine, Oncology, Pharmacology +14

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

T.M. Kim, S-Y Lee, Yoon Kyung Jeon et al. · Annals of Oncology · 2008 · 177 citations · Full text

Medicine, Oncology, Pathology +9

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

J.L. Lee, M.K. Kim, Inkeun Park et al. · Annals of Oncology · 2015 · 108 citations

Medicine, Oncology, Pharmacotherapy +10

High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients

Sung‐Yup Cho, Chang‐Ho Park, Deukchae Na et al. · Experimental & Molecular Medicine · 2017 · 68 citations · Full text

Medicine, Molecular Biology, Oncology +17